JP2006519610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006519610A5 JP2006519610A5 JP2006507095A JP2006507095A JP2006519610A5 JP 2006519610 A5 JP2006519610 A5 JP 2006519610A5 JP 2006507095 A JP2006507095 A JP 2006507095A JP 2006507095 A JP2006507095 A JP 2006507095A JP 2006519610 A5 JP2006519610 A5 JP 2006519610A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid compound
- ephb4
- ephrinb2
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 nucleic acid compound Chemical class 0.000 claims 99
- 108020004707 nucleic acids Proteins 0.000 claims 99
- 102000039446 nucleic acids Human genes 0.000 claims 99
- 210000004027 cell Anatomy 0.000 claims 32
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 238000000034 method Methods 0.000 claims 20
- 230000004962 physiological condition Effects 0.000 claims 18
- 108091030071 RNAI Proteins 0.000 claims 13
- 230000009368 gene silencing by RNA Effects 0.000 claims 13
- 230000033115 angiogenesis Effects 0.000 claims 11
- 230000000692 anti-sense effect Effects 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 230000004544 DNA amplification Effects 0.000 claims 3
- 102000006396 Ephrin-B2 Human genes 0.000 claims 3
- 108010044090 Ephrin-B2 Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000002255 enzymatic effect Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000008298 phosphoramidates Chemical class 0.000 claims 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 208000009056 telangiectasis Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000030797 EphB4 Receptor Human genes 0.000 claims 1
- 108010055323 EphB4 Receptor Proteins 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000001513 prostate squamous cell carcinoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000004862 vasculogenesis Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45443203P | 2003-03-12 | 2003-03-12 | |
| US45430003P | 2003-03-12 | 2003-03-12 | |
| US60/454,300 | 2003-03-12 | ||
| US60/454,432 | 2003-03-12 | ||
| PCT/US2004/007491 WO2004080418A2 (en) | 2003-03-12 | 2004-03-12 | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006519610A JP2006519610A (ja) | 2006-08-31 |
| JP2006519610A5 true JP2006519610A5 (enExample) | 2007-05-10 |
| JP4762889B2 JP4762889B2 (ja) | 2011-08-31 |
Family
ID=32994555
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507160A Pending JP2006521111A (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
| JP2006507095A Expired - Fee Related JP4762889B2 (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
| JP2011157200A Pending JP2011256179A (ja) | 2003-03-12 | 2011-07-15 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507160A Pending JP2006521111A (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011157200A Pending JP2011256179A (ja) | 2003-03-12 | 2011-07-15 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US7585967B2 (enExample) |
| EP (2) | EP1606305A4 (enExample) |
| JP (3) | JP2006521111A (enExample) |
| AU (3) | AU2004220459B2 (enExample) |
| CA (2) | CA2518898A1 (enExample) |
| WO (2) | WO2004080418A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| AU2002951409A0 (en) * | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
| WO2004028551A1 (en) | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| CA2518898A1 (en) * | 2003-03-12 | 2004-09-23 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
| US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| KR20120123619A (ko) | 2004-03-12 | 2012-11-08 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
| CA2559554A1 (en) | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| JP2007320850A (ja) * | 2004-08-24 | 2007-12-13 | Kyowa Hakko Kogyo Co Ltd | 抗エフリンｂ２抗体 |
| EP1799867A2 (en) * | 2004-09-23 | 2007-06-27 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
| WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| DE102004054016A1 (de) * | 2004-11-09 | 2006-05-11 | Robert Bosch Gmbh | Steuergerät zum Steuern und/oder regeln mindestens einer Fahrzeugfunktion |
| ES2556272T3 (es) * | 2004-11-18 | 2016-01-14 | The Board Of Trustees Of The University Of Illinois | Constructos de ARNsi multicistrónico para inhibir tumores |
| WO2006074392A2 (en) * | 2005-01-06 | 2006-07-13 | Genentech, Inc. | Cancer prognostic, diagnostic and treatment methods |
| US7582438B2 (en) | 2005-01-27 | 2009-09-01 | Burnham Institute For Medical Research | EphB receptor-binding peptides |
| FR2889200B1 (fr) | 2005-07-27 | 2008-01-04 | Inst Vaisseaux Et Du Sang Ass | Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique |
| CA2623387A1 (en) * | 2005-09-23 | 2007-04-05 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment or prevention of viral infections |
| KR101617108B1 (ko) | 2006-01-20 | 2016-04-29 | 제넨테크, 인크. | 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법 |
| DK2056845T3 (da) | 2006-08-08 | 2017-11-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | Struktur og anvendelse af 5'-phosphat-oligonukleotider |
| WO2009006336A1 (en) * | 2007-06-28 | 2009-01-08 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
| EP2185594B1 (en) * | 2007-08-13 | 2016-04-06 | VasGene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to ephb4 |
| US8357501B2 (en) | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
| AU2008328754B2 (en) * | 2007-11-29 | 2015-04-16 | Molecular Health Gmbh | Novel tissue protective erythropoietin receptor (NEPOR) and methods of use |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| US20120207743A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物 |
| WO2018110374A1 (ja) * | 2016-12-14 | 2018-06-21 | 国立大学法人信州大学 | 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球 |
| WO2020146723A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Functional analysis of cancer cells |
| JP7540010B2 (ja) * | 2020-05-28 | 2024-08-26 | サイトベイ インコーポレイテッド | 細胞病理染色 |
| EP4105328A1 (en) | 2021-06-15 | 2022-12-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression |
| US20250339504A1 (en) * | 2022-05-18 | 2025-11-06 | National Cancer Center | Cancer vaccine with use of common cancer antigen cocktail, tcr/car-t cell therapeutic, companion diagnostic method, and method for diagnosing risk of cancer onset by detecting circulating tumor cells |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| ES2230537T3 (es) | 1991-06-21 | 2005-05-01 | The Walter And Eliza Hall Institute Of Medical Research | Una tirosina quinasa de tipo receptor (quinasa de tipo eph/elk hunaba-henki y uso de la misma. |
| AU3482493A (en) | 1992-01-22 | 1993-09-01 | New England Deaconess Hospital | Novel protein tyrosine kinases |
| US5635177A (en) | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US6331302B1 (en) | 1992-01-22 | 2001-12-18 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
| US5824303A (en) | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
| JPH08505765A (ja) | 1992-11-13 | 1996-06-25 | アムジエン・インコーポレーテツド | Ｅｃｋ受容体リガンド |
| US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
| ES2152753B1 (es) | 1993-03-29 | 2001-09-01 | Ct Investig Energeticas Ciemat | Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5624899A (en) | 1994-07-20 | 1997-04-29 | Genentech Inc. | Method for using Htk ligand |
| WO1996003043A1 (en) | 1994-07-26 | 1996-02-08 | Rutgers, The State University Of New Jersey | Human brain specific kinase |
| US5795734A (en) * | 1994-09-19 | 1998-08-18 | President And Fellows Of Harvard College | EPH receptor ligands, and uses related thereto |
| EP0787148B1 (en) | 1994-10-27 | 2004-04-07 | Genentech, Inc. | Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| WO1996026958A2 (en) | 1995-02-27 | 1996-09-06 | President And Fellows Of Harvard College | Eph RECEPTOR LIGAND ELF-2 |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| AU710696C (en) | 1995-09-08 | 2002-10-24 | Genentech Inc. | VEGF-related protein |
| US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
| AUPN727795A0 (en) | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | A novel receptor-type tyrosine kinase and use thereof |
| US6696557B1 (en) * | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6413730B1 (en) * | 1996-07-05 | 2002-07-02 | Mount Sinai Hospital Corporation | Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| DK1325932T5 (da) | 1997-04-07 | 2005-10-03 | Genentech Inc | Anti-VEGF antistoffer |
| WO1998045708A1 (en) | 1997-04-08 | 1998-10-15 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
| US6440954B1 (en) * | 1997-04-18 | 2002-08-27 | President And Fellows Of Harvard College | Inhibition of vascular smooth muscle cell proliferation |
| WO1999008696A1 (en) | 1997-08-19 | 1999-02-25 | Vanderbilt University | METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS |
| JP2001518318A (ja) * | 1997-10-02 | 2001-10-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Ｌｅｒｋ−２媒介細胞接着の調節 |
| US6423685B1 (en) * | 1998-03-05 | 2002-07-23 | Chiron Corporation | Method for increasing the serum half-life of a biologically active molecule |
| US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| EP0999278B1 (en) | 1998-10-02 | 2004-03-31 | Universite Paris Vii | Vascular specific regulatory elements contained in the desmin 5' flanking region |
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| DK1135153T3 (da) * | 1998-11-20 | 2005-08-15 | Genentech Inc | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser |
| US6150162A (en) * | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
| US6770633B1 (en) * | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| AU2658701A (en) * | 2000-01-06 | 2001-07-16 | Hospital For Sick Children, The | Methods of modulation of the immune system |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| WO2001072765A1 (en) * | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals, Inc. | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING |
| AU2001266557A1 (en) * | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2001081377A2 (en) | 2000-04-21 | 2001-11-01 | Amgen, Inc. | Integrin/adhesion antagonists |
| US6271030B1 (en) * | 2000-06-14 | 2001-08-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of C/EBP beta expression |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| AU2001283108A1 (en) | 2000-08-03 | 2002-02-18 | The University Of Utah Research Foundation | Manipulation of arterial-venous identity |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| AU2002212292A1 (en) | 2000-09-29 | 2002-04-08 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
| US7136808B2 (en) * | 2000-10-20 | 2006-11-14 | Microsoft Corporation | Detection and correction of errors in german grammatical case |
| US7163808B2 (en) * | 2000-11-20 | 2007-01-16 | California Institute Of Technology | Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| WO2002058538A2 (en) | 2001-01-26 | 2002-08-01 | Regeneron Pharmaceuticals, Inc. | Methods of imaging and targeting vasculature |
| CA2437194A1 (en) | 2001-01-31 | 2002-08-08 | Mount Sinai Hospital | Methods for regulating the kinase domain of ephb2 |
| CA2434881A1 (en) | 2001-02-02 | 2002-08-15 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Method for identifying functional nucleic acids |
| JP2004532022A (ja) * | 2001-03-26 | 2004-10-21 | サーナ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害 |
| AU2002311792A1 (en) | 2001-03-30 | 2002-10-15 | President And Fellows Of Harvard College | B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use |
| CA2448320A1 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
| EP2000148A1 (en) * | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of prostate cancer |
| JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
| US20040247592A1 (en) * | 2001-07-03 | 2004-12-09 | Roifman Chaim M. | Ephrin and eph receptor mediated immune modulation |
| JP3876656B2 (ja) * | 2001-07-13 | 2007-02-07 | 住友金属工業株式会社 | 管用ねじ継手 |
| WO2003040317A2 (en) * | 2001-11-02 | 2003-05-15 | Pfizer Products Inc. | Lung cancer therapeutics and diagnostics |
| US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
| WO2003094859A2 (en) | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| EP1575509B1 (en) | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| US20040110150A1 (en) | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of Ephrin-B2 expression |
| WO2004020468A2 (en) | 2002-08-28 | 2004-03-11 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| AU2002951409A0 (en) | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
| AU2003260169B9 (en) * | 2002-09-16 | 2011-06-09 | The Queen Elizabeth Hospital Research Foundation Inc. | Methods for regulating cancer |
| EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US7250289B2 (en) * | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
| CA2518898A1 (en) * | 2003-03-12 | 2004-09-23 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
| US20070207952A1 (en) * | 2003-03-24 | 2007-09-06 | Sequoia Pharmaceuticals | Long Acting Biologically Active Conjugates |
| JP2006524693A (ja) | 2003-04-11 | 2006-11-02 | メディミューン，インコーポレーテッド | ＥｐｈＡ２および非腫瘍性過増殖性細胞障害 |
| WO2004092343A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| WO2005048917A2 (en) | 2003-06-06 | 2005-06-02 | Medimmune, Inc. | Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer |
| WO2005037232A2 (en) * | 2003-10-17 | 2005-04-28 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
| CN1905899B (zh) | 2003-11-20 | 2011-09-28 | 医学免疫公司 | EphA2激动性单克隆抗体及其使用方法 |
| CA2559554A1 (en) | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
-
2004
- 2004-03-12 CA CA002518898A patent/CA2518898A1/en not_active Abandoned
- 2004-03-12 US US10/800,077 patent/US7585967B2/en not_active Expired - Fee Related
- 2004-03-12 AU AU2004220459A patent/AU2004220459B2/en not_active Ceased
- 2004-03-12 JP JP2006507160A patent/JP2006521111A/ja active Pending
- 2004-03-12 EP EP04720327A patent/EP1606305A4/en not_active Withdrawn
- 2004-03-12 US US10/800,350 patent/US7862816B2/en not_active Expired - Fee Related
- 2004-03-12 JP JP2006507095A patent/JP4762889B2/ja not_active Expired - Fee Related
- 2004-03-12 WO PCT/US2004/007491 patent/WO2004080418A2/en not_active Ceased
- 2004-03-12 EP EP20040720444 patent/EP1605961A4/en not_active Withdrawn
- 2004-03-12 AU AU2004220525A patent/AU2004220525B2/en not_active Ceased
- 2004-03-12 WO PCT/US2004/007755 patent/WO2004080425A2/en not_active Ceased
- 2004-03-12 CA CA002518912A patent/CA2518912A1/en not_active Abandoned
-
2006
- 2006-10-06 US US11/544,855 patent/US8063183B2/en not_active Expired - Fee Related
-
2009
- 2009-09-01 US US12/552,185 patent/US20100093831A1/en not_active Abandoned
-
2010
- 2010-11-01 AU AU2010238577A patent/AU2010238577B2/en not_active Ceased
- 2010-11-23 US US12/952,593 patent/US20110129482A1/en not_active Abandoned
-
2011
- 2011-07-15 JP JP2011157200A patent/JP2011256179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006519610A5 (enExample) | ||
| Massagué et al. | Metastatic colonization by circulating tumour cells | |
| Nosrati et al. | Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA | |
| Ovechkin et al. | Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice | |
| JP2019500347A5 (enExample) | ||
| JP7553036B2 (ja) | ｓｎｏＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| Kohnken et al. | MicroRNAs in cutaneous T-cell lymphoma: the future of therapy | |
| KR20220113999A (ko) | 종양 마커 및 치료 표적으로서의 긴 비-코딩 rna letn | |
| JP6262707B2 (ja) | がん幹細胞を含むまたはそれに由来するがんの治療、予防および診断のための方法および組成物 | |
| US20160362693A1 (en) | Reagents and Methods for Treating Cancer | |
| Wang et al. | Regression of atherosclerosis plaques in apolipoprotein E−/− mice after lentivirus-mediated RNA interference of CD40 | |
| WO2021010449A1 (ja) | Ｒｎａ分子、キメラ型ｎａ分子、二本鎖ｒｎａ分子、および二本鎖キメラ型ｎａ分子 | |
| Mustfa et al. | Porous Silicon Nanoneedles Efficiently Deliver Adenine Base Editor to Correct a Recurrent Pathogenic COL7A1 Variant in Recessive Dystrophic Epidermolysis Bullosa | |
| Profumo et al. | Targeting microRNAs to withstand cancer metastasis | |
| CN108977443A (zh) | 一种表达动脉粥样硬化炎症活动的环状rna及其应用 | |
| McMurry et al. | Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications | |
| Sun et al. | Circ_0049979 ameliorates myocardial infarction through improving Cx43-mediated endothelial functions | |
| US20200095583A1 (en) | Methods and Compositions for Managing Vascular Conditions | |
| JPWO2006132204A1 (ja) | 転写因子デコイ | |
| Farhadi et al. | The potential role of circular RNAs in regulating p53 in different types of cancers | |
| KR20130014840A (ko) | ｍｉＲ-636을 이용한 간암 치료 및 진단 방법 | |
| Song et al. | Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme | |
| CN110358765A (zh) | 抑制人TNFAIP1基因表达的siRNA及其应用 | |
| JP7498448B2 (ja) | ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| CN113373177A (zh) | 一种提高胶质母细胞瘤替莫唑胺疗效的方法 |